These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 38470509)

  • 21. Pathologic Alterations in the Proteome of Synaptosomes from a Mouse Model of Spinal Muscular Atrophy.
    Eshraghi M; Gombar R; De Repentigny Y; Vacratsis PO; Kothary R
    J Proteome Res; 2019 Aug; 18(8):3042-3051. PubMed ID: 31262178
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Fasudil improves survival and promotes skeletal muscle development in a mouse model of spinal muscular atrophy.
    Bowerman M; Murray LM; Boyer JG; Anderson CL; Kothary R
    BMC Med; 2012 Mar; 10():24. PubMed ID: 22397316
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Nusinersen ameliorates motor function and prevents motoneuron Cajal body disassembly and abnormal poly(A) RNA distribution in a SMA mouse model.
    Berciano MT; Puente-Bedia A; Medina-Samamé A; Rodríguez-Rey JC; Calderó J; Lafarga M; Tapia O
    Sci Rep; 2020 Jul; 10(1):10738. PubMed ID: 32612161
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cerebrospinal fluid characteristics of patients treated with intrathecal nusinersen for spinal muscular atrophy.
    Orbach R; Sagi L; Sadot E; Tokatly Latzer I; Shtamler A; Zisberg T; Fattal-Valevski A
    Muscle Nerve; 2022 Dec; 66(6):762-766. PubMed ID: 36214191
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Proteomic assessment of a cell model of spinal muscular atrophy.
    Wu CY; Whye D; Glazewski L; Choe L; Kerr D; Lee KH; Mason RW; Wang W
    BMC Neurosci; 2011 Mar; 12():25. PubMed ID: 21385431
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Chronic treatment with lithium does not improve neuromuscular phenotype in a mouse model of severe spinal muscular atrophy.
    Dachs E; Piedrafita L; Hereu M; Esquerda JE; Calderó J
    Neuroscience; 2013 Oct; 250():417-33. PubMed ID: 23876328
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nusinersen for Spinal Muscular Atrophy in the United States: Findings From a Retrospective Claims Database Analysis.
    Gauthier-Loiselle M; Cloutier M; Toro W; Patel A; Shi S; Davidson M; Bischof M; LaMarca N; Dabbous O
    Adv Ther; 2021 Dec; 38(12):5809-5828. PubMed ID: 34713391
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Analysis of Free Circulating Messenger Ribonucleic Acids in Serum Samples from Late-Onset Spinal Muscular Atrophy Patients Using nCounter NanoString Technology.
    Leo M; Schmitt LI; Mairinger F; Roos A; Hansmann C; Hezel S; Skuljec J; Pul R; Schara-Schmidt U; Kleinschnitz C; Hagenacker T
    Cells; 2023 Sep; 12(19):. PubMed ID: 37830588
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Drug treatment for spinal muscular atrophy types II and III.
    Wadman RI; van der Pol WL; Bosboom WM; Asselman FL; van den Berg LH; Iannaccone ST; Vrancken AF
    Cochrane Database Syst Rev; 2020 Jan; 1(1):CD006282. PubMed ID: 32006461
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Non-aggregating tau phosphorylation by cyclin-dependent kinase 5 contributes to motor neuron degeneration in spinal muscular atrophy.
    Miller N; Feng Z; Edens BM; Yang B; Shi H; Sze CC; Hong BT; Su SC; Cantu JA; Topczewski J; Crawford TO; Ko CP; Sumner CJ; Ma L; Ma YC
    J Neurosci; 2015 Apr; 35(15):6038-50. PubMed ID: 25878277
    [TBL] [Abstract][Full Text] [Related]  

  • 31. ZPR1 prevents R-loop accumulation, upregulates SMN2 expression and rescues spinal muscular atrophy.
    Kannan A; Jiang X; He L; Ahmad S; Gangwani L
    Brain; 2020 Jan; 143(1):69-93. PubMed ID: 31828288
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Nusinersen treatment of spinal muscular atrophy - a systematic review.
    Albrechtsen SS; Born AP; Boesen MS
    Dan Med J; 2020 Aug; 67(9):. PubMed ID: 32800069
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Muscle microRNAs in the cerebrospinal fluid predict clinical response to nusinersen therapy in type II and type III spinal muscular atrophy patients.
    Magen I; Aharoni S; Yacovzada NS; Tokatly Latzer I; Alves CRR; Sagi L; Fattal-Valevski A; Swoboda KJ; Katz J; Bruckheimer E; Nevo Y; Hornstein E
    Eur J Neurol; 2022 Aug; 29(8):2420-2430. PubMed ID: 35510740
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comprehensive Mutation Analysis and Report of 12 Novel Mutations in a Cohort of Patients with Spinal Muscular Atrophy in Iran.
    Sharifi Z; Taheri M; Fallah MS; Abiri M; Golnabi F; Bagherian H; Zeinali R; Farahzadi H; Alborji M; Tehrani PG; Amini M; Asnavandi S; Hashemi M; Forouzesh F; Zeinali S
    J Mol Neurosci; 2021 Nov; 71(11):2281-2298. PubMed ID: 33481221
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cell-mediated cytotoxicity within CSF and brain parenchyma in spinal muscular atrophy unaltered by nusinersen treatment.
    Lu IN; Cheung PF; Heming M; Thomas C; Giglio G; Leo M; Erdemir M; Wirth T; König S; Dambietz CA; Schroeter CB; Nelke C; Siveke JT; Ruck T; Klotz L; Haider C; Höftberger R; Kleinschnitz C; Wiendl H; Hagenacker T; Meyer Zu Horste G
    Nat Commun; 2024 May; 15(1):4120. PubMed ID: 38750052
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Selective loss of alpha motor neurons with sparing of gamma motor neurons and spinal cord cholinergic neurons in a mouse model of spinal muscular atrophy.
    Powis RA; Gillingwater TH
    J Anat; 2016 Mar; 228(3):443-51. PubMed ID: 26576026
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Disease Modifying Therapies for the Management of Children with Spinal Muscular Atrophy (5q SMA): An Update on the Emerging Evidence.
    Hjartarson HT; Nathorst-Böös K; Sejersen T
    Drug Des Devel Ther; 2022; 16():1865-1883. PubMed ID: 35734367
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-Term Comparative Efficacy and Safety of Risdiplam and Nusinersen in Children with Type 1 Spinal Muscular Atrophy.
    Kokaliaris C; Evans R; Hawkins N; Mahajan A; Scott DA; Sutherland CS; Nam J; Sajeev G
    Adv Ther; 2024 Jun; 41(6):2414-2434. PubMed ID: 38705943
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dysregulation of Tweak and Fn14 in skeletal muscle of spinal muscular atrophy mice.
    Meijboom KE; Sutton ER; McCallion E; McFall E; Anthony D; Edwards B; Kubinski S; Tapken I; Bünermann I; Hazell G; Ahlskog N; Claus P; Davies KE; Kothary R; Wood MJA; Bowerman M
    Skelet Muscle; 2022 Jul; 12(1):18. PubMed ID: 35902978
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The light at the end of the tunnel gets vivid for spinal muscular atrophy: An Editorial Highlight for "Cerebrospinal fluid proteomic profiling in nusinersen-treated patients with spinal muscular atrophy" on page 650.
    Dutta D; Chandra G; Mohanakumar KP
    J Neurochem; 2020 Jun; 153(5):545-548. PubMed ID: 32128827
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.